Our finding that the plasma levels of CXCL16 were significantly higher in normal LF smokers (pre-COPD) and GOLD 1 patients than in control subjects suggests that circulating CXCL16 levels could be a new peripheral biomarker for COPD development in the susceptible population. This evidence concerns the gene CXCL16 and chronic obstructive pulmonary disease.